296 related articles for article (PubMed ID: 12515565)
1. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
File TM; Tan JS
Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
[TBL] [Abstract][Full Text] [Related]
2. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
[TBL] [Abstract][Full Text] [Related]
3. Appropriate outpatient macrolide use in community-acquired pneumonia.
Gotfried MH
J Am Acad Nurse Pract; 2004 Apr; 16(4):146, 148, 150 passim. PubMed ID: 15137473
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
File TM; Garau J; Blasi F; Chidiac C; Klugman K; Lode H; Lonks JR; Mandell L; Ramirez J; Yu V
Chest; 2004 May; 125(5):1888-901. PubMed ID: 15136404
[TBL] [Abstract][Full Text] [Related]
5. Macrolide Resistance in
Schroeder MR; Stephens DS
Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
[No Abstract] [Full Text] [Related]
6. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices.
Bartlett JG
Semin Respir Infect; 1997 Dec; 12(4):329-33. PubMed ID: 9436960
[TBL] [Abstract][Full Text] [Related]
7. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines].
Oosterheert JJ; Bonten MJ; Schneider MM; Hoepelman IM
Ned Tijdschr Geneeskd; 2003 Mar; 147(9):381-6. PubMed ID: 12661455
[TBL] [Abstract][Full Text] [Related]
8. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
Lynch III JP; Martinez FJ
Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
[TBL] [Abstract][Full Text] [Related]
10. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
11. Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department.
Haran JP; Volturo GA
J Emerg Med; 2018 Sep; 55(3):347-353. PubMed ID: 29789175
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study.
Schito GC; Marchese A; Elkharrat D; Farrell DJ;
J Chemother; 2004 Feb; 16(1):13-22. PubMed ID: 15077994
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of azithromycin as the empiric therapy in children with community-acquired pneumonia who were isolated macrolide resistant Streptococcus pneumoniae from nasopharynx].
Nariai A; Okitsu N; Inoue M
Kansenshogaku Zasshi; 2004 Jun; 78(6):490-5. PubMed ID: 15287476
[TBL] [Abstract][Full Text] [Related]
14. Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004).
Wierzbowski AK; Nichol K; Laing N; Hisanaga T; Nikulin A; Karlowsky JA; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2007 Oct; 60(4):733-40. PubMed ID: 17673477
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of Macrolide-Induced Inhibition of Pneumolysin Release Involves Impairment of Autolysin Release in Macrolide-Resistant Streptococcus pneumoniae.
Domon H; Maekawa T; Yonezawa D; Nagai K; Oda M; Yanagihara K; Terao Y
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181369
[No Abstract] [Full Text] [Related]
16. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4.
Jenkins SG; Brown SD; Farrell DJ
Ann Clin Microbiol Antimicrob; 2008 Jan; 7():1. PubMed ID: 18190701
[TBL] [Abstract][Full Text] [Related]
17. [Survey of macrolide resistance in Mycoplasma pneumoniae in adult patients with community-acquired pneumonia in Beijing, China].
Yin YD; Cao B; Wang H; Wang RT; Liu YM; Gao Y; Qu JX; Han GJ; Liu YN
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):954-8. PubMed ID: 24503430
[TBL] [Abstract][Full Text] [Related]
18. Community-acquired pneumonia: the evolving challenge.
Finch R
Clin Microbiol Infect; 2001; 7 Suppl 3():30-8. PubMed ID: 11523560
[TBL] [Abstract][Full Text] [Related]
19. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
20. The use of macrolides in treatment of upper respiratory tract infections.
Wierzbowski AK; Hoban DJ; Hisanaga T; DeCorby M; Zhanel GG
Curr Allergy Asthma Rep; 2006 Mar; 6(2):171-81. PubMed ID: 16566868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
